J&J reports 56-week data for Tremfya in psoriatic arthritis

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported additional data from a Phase II trial of Tremfya guselkumab (CNTO 1959)showing that the drug maintained efficacy through 56 weeks in patients with active psoriatic arthritis.

In the 149-patient trial, 74% of patients who received 100 mg subcutaneous Tremfya at weeks 0 and 4 and then every 8 weeks through week 44 achieved a 20% improvement in the American College of Rheumatology criteria (ACR20) at week 56, with 53% of patients achieving an ACR50 response at week 56. Additionally, 85%, 78% and 57% of patients in the Tremfya arm achieved a Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response, respectively, at week 56. Data were presented at the American College of Rheumatology/Association of Rheumatology Health Professionals meeting in San Diego...